LeJeune Puetz Investment Counsel’s Myriad Genetics MYGN Stock Holding History

LeJeune Puetz Investment Counsel’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-10,000	Closed	-$113K	–	173
2020 Q2	$113K	Sell	10,000 -1,925	-16%	-$27.3K	0.06%	162
2020 Q1	$171K	Sell	11,925 -8,000	-40%	-$169K	0.1%	140
2019 Q4	$543K	Sell	19,925 -6,000	-23%	-$165K	0.25%	100
2019 Q3	$742K	Sell	25,925 -700	-3%	-$20.4K	0.38%	78
2019 Q2	$740K	Buy	26,625 +700	+3%	+$19.8K	0.38%	76
2019 Q1	$861K	Buy	25,925 +1,000	+4%	+$30.4K	0.47%	65
2018 Q4	$725K	Buy	24,925 +400	+2%	+$14.4K	0.45%	68
2018 Q3	$1.13M	Hold	24,525	–	–	0.65%	57
2018 Q2	$916K	Sell	24,525 -4,500	-16%	-$152K	0.57%	64
2018 Q1	$858K	Hold	29,025	–	–	0.53%	67
2017 Q4	$997K	Hold	29,025	–	–	0.61%	60
2017 Q3	$1.05M	Sell	29,025 -2,000	-6%	-$57K	0.68%	57
2017 Q2	$802K	Buy	31,025 +1,000	+3%	+$21.2K	0.54%	68
2017 Q1	$576K	Buy	30,025 +2,000	+7%	+$35.4K	0.41%	84
2016 Q4	$467K	Buy	+28,025	New	+$507K	0.36%	91

Other funds holding MYGN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

GCM

Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return

DGI

Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

LeJeune Puetz Investment Counsel's MYGN Position: Q3 2020 in Review

LeJeune Puetz Investment Counsel sold out of Myriad Genetics (MYGN) in Q3 2020, closing a stake of 10,000 shares — an estimated $113K sold.

LeJeune Puetz Investment Counsel first reported a position in MYGN in Q4 2016 and held it in 15 quarters. The position peaked at $1.13M in Q3 2018. 192 funds tracked by Wall St. Rank hold MYGN as of Q3 2020.

LeJeune Puetz Investment Counsel reported no remaining Myriad Genetics position as of Q3 2020 after selling out during the quarter.
LeJeune Puetz Investment Counsel sold 10,000 Myriad Genetics shares in Q3 2020, an estimated $113K.
LeJeune Puetz Investment Counsel first reported a position in Myriad Genetics in Q4 2016 and held it in 15 quarters.
LeJeune Puetz Investment Counsel's Myriad Genetics position peaked at $1.13M in Q3 2018.
192 funds tracked by Wall St. Rank held Myriad Genetics as of Q3 2020.

Based on LeJeune Puetz Investment Counsel's 13F filing for Q3 2020, filed 3 Nov 2020.